MRNA cancer therapy enters human testing for tough blood cancers
NCT ID NCT07332663
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This early-phase trial tests a new mRNA drug (WGb-0301) for people with B-cell blood cancers that have come back or not responded to standard treatments. The drug uses lipid nanoparticles to deliver mRNA that targets CD19 on cancer cells, aiming to clear them safely. Only 9 participants will be enrolled to find the safest dose and check for early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.